About 2 months of the estimated/stated duration (9 months) of the pharma negotiations has passed. Herantis’ board has certainly been meeting intensively, and a decision regarding the future will likely soon be ready for a stock exchange release.
Only the stock market’s “neighbor envy” keeps this in a grip, but for how long.
Actually, no negative press releases or actions have been seen in this company’s operations or development work for many years.
Herantis Pharma’s CEO Antti Vuolanto talked about his company as an investment 
\n\nHerantis Pharma sijoituskohteena | Pörssisijoittajan viikko 14.9.2026 - Inderes
https://x.com/ristopar/status/2084489876674638141/video/1
Good newsletter from Michael J. Fox Foundation
The Michael J. Fox Foundation has an ambitious Strategic Research Agenda to guide the field over the coming years.
The plan aligns with our goals to identify and move forward the research closest or most critical to patient relevance, avoid duplication of efforts and leverage donor dollars to go as far as possible. In short, find the research with the best odds and then go all in.
The Foundation’s Strategic Research Agenda has four interrelated pillars:
Gift article by BARRONS on current medical innovations,
https://www.barrons.com/articles/biotech-stocks-to-buy-roundtable-picks-057abe29?st=eEBhH6
Tavapadon has received FDA approval for the treatment of Parkinson’s disease: https://www.fiercepharma.com/pharma/abbvies-cerevel-buyout-delivers-fda-gives-go-ahead-1st-class-juvmo-parkinsons-disease. In terms of its mechanism of action, it is a dopamine receptor agonist, meaning it is not a competitor to HER096, but rather primarily to levodopa.
It might be a good idea for Herantis Pharma and HER-096 to try a BIG Fish?
https://www.barrons.com/articles/eli-lilly-stock-merida-biosciences-acquisition-3757be2f?st=kSxb3m
Lilly Stock Rises
